{"id":"NCT00129935","sponsor":"Spanish Breast Cancer Research Group","briefTitle":"EC Followed Docetaxel Versus ET Followed Capecitabine as Adjuvant Chemotherapy for Node Positive Operable Breast Cancer","officialTitle":"Phase III Trial to Compare Epirubicin and Cyclophosphamide (EC) Followed by Docetaxel (T) to Epirubicin and Docetaxel (ET) Followed by Capecitabine (X) as Adjuvant Treatment, Node Positive Breast Cancer Patients","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2004-02","primaryCompletion":"2013-06","completion":"2019-04-04","firstPosted":"2005-08-12","resultsPosted":"2019-10-25","lastUpdate":"2023-03-31"},"enrollment":1384,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Breast Cancer"],"interventions":[{"type":"DRUG","name":"Docetaxel","otherNames":["Taxotere"]},{"type":"DRUG","name":"Capecitabine","otherNames":["Xeloda"]},{"type":"DRUG","name":"Epirubicin","otherNames":["Ellence"]},{"type":"DRUG","name":"Cyclophosphamide","otherNames":["cytoxan"]}],"arms":[{"label":"Arm A: EC-T","type":"ACTIVE_COMPARATOR"},{"label":"Arm B: ET-X","type":"EXPERIMENTAL"}],"summary":"This is a prospective, randomised phase III trial, to compare the efficacy and safety profiles of two types of adjuvant chemotherapy regimens for human epidermal growth factor receptor 2 (HER2) negative, node positive breast cancer patients.\n\nControl Arm: This includes 4 cycles of EC 90/600 mg/m2 day 1 every 3 weeks, followed by 4 cycles of T 100 mg/m2 day 1 every 3 weeks.\n\nExperimental Arm: This includes 4 cycles of ET 90/75 mg/m2, day 1 every 3 weeks, followed by 4 cycles of capecitabine 1250 mg/m2, twice a day, via oral intake, for 14 days, and then a one-week rest period.\n\nPremenopausal women with hormone receptor positive tumours must receive 5 years of tamoxifen after the end of chemotherapy.\n\nPostmenopausal women with hormone receptor positive tumours can receive tamoxifen or aromatase inhibitors (or both) after the end of chemotherapy.\n\nPatients may receive radiotherapy when clinically indicated.","primaryOutcome":{"measure":"Number of Participants With Disease-free Survival (DFS) Event","timeFrame":"5 years","effectByArm":[{"arm":"Arm A: EC-T","deltaMin":127,"sd":null},{"arm":"Arm B: ET-X","deltaMin":170,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"FEMALE","healthyVolunteers":false,"inclusionCount":13,"exclusionCount":20},"locations":{"siteCount":58,"countries":["Spain"]},"refs":{"pmids":["26416999","35305453","37338729","34037241"],"seeAlso":["http://www.geicam.org"]},"adverseEventsSummary":{"seriousAny":{"events":111,"n":669},"commonTop":["ALOPECIA","FATIGUE","Nausea","IRREGULAR MENSES","STOMATITIS/PHARYNGITIS (ORAL/PHARYNGEAL MUCOSITIS)"]}}